Illumina Inc
Closed
SectorHealthcare
185.67 -2.84
Overview
Share price change
24h
Min
188.82
Max
196.02
Income | -200M 134M |
|---|---|
Sales | -68M 1.1B |
P/E Sector Avg | 32.042 56.269 |
EPS | 1.15 |
Profit margin | 12.282 |
Employees | 8,600 |
EBITDA | -219M 226M |
Recommendations | Buy |
|---|---|
12 Months Forecast | -18.4% downside |
Next Earnings | 30 lip 2026 |
|---|
Market Cap | 7.2B 27B |
|---|---|
Previous open | 188.51 |
Previous close | 185.67 |
Illumina Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Illumina Inc Forecast
Price Target
By TipRanks
-18.4% downside
12 Months Forecast
Average 158.57 USD -18.4%
High 200 USD
Low 95 USD
Based on 14 Wall Street analysts offering 12 month price targets forIllumina Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Illumina Inc
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
